AbCellera Reports Q3 2026 Business Results
AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE AbCellera Reports Q3 2026 Business Results 11/9/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars,
How this was made
The 30-second read
Why it matters
The combination of a sizable capital raise and positive trial data provides a fresh catalyst for the stock.
Market read
First‑report earnings and trial data are material for traders targeting biotech equities.
What to watch
Potential dilution from the $200M offering and the decision not to advance ABCL575 beyond Phase 1.
Q3 2026 net loss narrowed to $40.8 million from $57.1 million as R&D and SG&A fell; $200 million equity raise lifted reported liquidity to over $890 million
Quarterly total revenue rose to $10,639 thousand from $8,955 thousand, operating expenses fell to $63,954 thousand from $85,233 thousand, and the net loss narrowed to $(40,758) thousand from $(57,119) thousand. Nine-month revenue declined to $23,001 thousand from $30,275 thousand, and the company reported no guidance, so the read rests on quarterly cost reduction, the Phase 2 and Phase 1 readouts and a stronger balance sheet.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q3 2026GAAP | $10.64M | – | – |
| Research fees, Q3 2026GAAP | $10.55M | – | – |
| Licensing and royalty revenue, Q3 2026GAAP | $90K | – | – |
| Research and development expenses, Q3 2026 (exclusive of depreciation and amortization)GAAP | $43.53M | – | – |
| Sales, general and administrative expenses, Q3 2026 (exclusive of depreciation and amortization)GAAP | $13.61M | – | – |
| Depreciation and amortization, Q3 2026GAAP | $6.81M | – | – |
| Total operating expenses, Q3 2026GAAP | $63.95M | – | – |
| Loss from operations, Q3 2026GAAP | −$53.31M | – | – |
| Interest and other, Q3 2026 (presented within other income)GAAP | −$6.87M | – | – |
| Grants and incentives, Q3 2026 (presented within other income)GAAP | −$3.64M | – | – |
| Total other income, Q3 2026GAAP | −$10.50M | – | – |
| Loss before income tax, Q3 2026GAAP | −$42.81M | – | – |
| Income tax recovery, Q3 2026GAAP | −$2.05M | – | – |
| Net loss, Q3 2026GAAP | −$40.76M | – | – |
| Comprehensive loss, Q3 2026GAAP | −$41.03M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.13) | – | – |
| Total revenue, nine months ended Sept 30, 2026GAAP | $23.00M | – | – |
| Research fees, nine months ended Sept 30, 2026GAAP | $22.57M | – | – |
| Licensing and royalty revenue, nine months ended Sept 30, 2026GAAP | $431K | – | – |
| Research and development expenses, nine months ended Sept 30, 2026 (exclusive of depreciation and amortization)GAAP | $136.2M | – | – |
| Sales, general and administrative expenses, nine months ended Sept 30, 2026 (exclusive of depreciation and amortization)GAAP | $39.80M | – | – |
| Depreciation and amortization, nine months ended Sept 30, 2026GAAP | $20.63M | – | – |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $196.6M | – | – |
| Loss from operations, nine months ended Sept 30, 2026GAAP | −$173.6M | – | – |
| Interest and other, nine months ended Sept 30, 2026 (presented within other income)GAAP | −$10.47M | – | – |
| Grants and incentives, nine months ended Sept 30, 2026 (presented within other income)GAAP | −$11.83M | – | – |
| Total other income, nine months ended Sept 30, 2026GAAP | −$22.30M | – | – |
| Loss before income tax, nine months ended Sept 30, 2026GAAP | −$151.3M | – | – |
| Income tax recovery, nine months ended Sept 30, 2026GAAP | −$11.96M | – | – |
| Net loss, nine months ended Sept 30, 2026GAAP | −$139.3M | – | – |
| Comprehensive loss, nine months ended Sept 30, 2026GAAP | −$138.5M | – | – |
| Net loss per share, basic and diluted, nine months ended Sept 30, 2026GAAP | $(0.45) | – | – |
| Total cash, cash equivalents and marketable securities, Sept 30, 2026 (balance sheet)GAAP | $764.4M | – | – |
| Total assets, Sept 30, 2026GAAP | $1.50B | – | – |
| Total liabilities, Sept 30, 2026GAAP | $437.4M | – | – |
| Total shareholders' equity, Sept 30, 2026GAAP | $1.06B | – | – |
| Net cash provided by (used in) operating activities, nine months ended Sept 30, 2026GAAP | $19.31M | – | – |
| Net cash provided by (used in) investing activities, nine months ended Sept 30, 2026GAAP | −$197.2M | – | – |
| Net cash provided by financing activities, nine months ended Sept 30, 2026GAAP | $214.2M | – | – |
| Purchases of property and equipment, nine months ended Sept 30, 2026GAAP | −$7.58M | – | – |
| Issuance of common shares and pre-funded warrants, net, nine months ended Sept 30, 2026GAAP | $188.8M | – | – |
| Partner-led programs with downstream stake progressing, Sept 30, 2026other | 34 | – | – |
| Downstream stakes in molecules in the clinic understood to be progressing, Sept 30, 2026other | 12 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Research fees (revenue line)The filing does not explain this line. | $10,549 thousand (Q3 2026); $22,570 thousand (nine months ended Sept 30, 2026) | – | – |
| Licensing and royalty revenue (revenue line)The filing does not explain this line. | $90 thousand (Q3 2026); $431 thousand (nine months ended Sept 30, 2026) | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Nine-month proceeds from issuance of common shares and pre-funded warrants, net, were $188,824 thousand, per the cash flow statement. The filing states the company completed a $200 million offering of common shares and pre-funded warrants in Q3 2026.
What drove it
- Company states Q3 2026 net loss was $40.8 million, compared with $57.1 million in Q3 2025.
- Company states that following the capital raise and positive year-to-date operating cashflow, its total cash balances and marketable securities exceed $790 million.
- Company announced positive top-line Phase 2 results for ABCL635 and plans late-stage development for menopausal VMS in 2027, plus trials in VMS caused by hormone suppression associated with breast and prostate cancer treatment, expected to start in 2027.
- Company announced top-line Phase 1 data for ABCL575 (OX40 ligand, atopic dermatitis) in a subsequent event; the company currently does not plan to develop ABCL575 past Phase 1.
- Company reports R&D expenses of $43.5 million, down from $55.0 million, and SG&A expenses of $13.6 million, down from $25.0 million, in Q3 2025.
Concerns
- Nine-month total revenue was $23,001 thousand versus $30,275 thousand, driven by licensing and royalty revenue of $431 thousand versus $10,751 thousand in the prior-year nine months.
- Depreciation and amortization rose to $6,806 thousand in Q3 2026 from $5,247 thousand, and to $20,634 thousand for nine months from $16,048 thousand, although the company does not comment on the increase.
- Partner-led programs with a downstream stake fell to 34 at Sept 30, 2026 from 44 at Dec 31, 2025.
- ABCL575 will not be developed past Phase 1 according to the filing.
- Nine-month investing cash outflow was $(197,176) thousand, mainly from net purchases of marketable securities, and the filing does not give a free cash flow figure.
- Equity was issued in the quarter, increasing shares outstanding to 326,332,641 at Sept 30, 2026 from 300,600,710 at Dec 31, 2025 (share counts are noted here for context only).
What to watch
- Timing and design of the planned 2027 late-stage menopausal VMS program for ABCL635 and the two oncology-related VMS trials.
- Progress of ABCL992, ABCL385 and ABCL646 through IND-enabling activities.
- Continued advancement of ABCL386 and ABCL688 through IND-enabling activities.
- Trend in licensing and royalty revenue, which was $90 thousand in Q3 2026 versus $138 thousand in Q3 2025.
- Whether the stated $100 million of non-dilutive government funding becomes available as described.
- Reconciliation between the press release liquidity figures and the balance sheet cash and marketable securities total in future filings.
Balance sheet and cash flow
- Balance sheet at Sept 30, 2026: cash and cash equivalents $163,800 thousand; marketable securities $600,624 thousand; total cash, cash equivalents and marketable securities $764,424 thousand; restricted cash $25,000 thousand; accounts and accrued receivables $17,964 thousand.
- Deferred revenue at Sept 30, 2026: current $35,038 thousand and long-term $48,050 thousand, versus $13,526 thousand and $3,500 thousand at Dec 31, 2025.
- Operating lease liability (long-term) $128,130 thousand at Sept 30, 2026 versus $137,403 thousand at Dec 31, 2025. Deferred government contributions (long-term) $180,275 thousand versus $174,453 thousand.
- Nine-month cash flow: operating activities provided $19,313 thousand versus used $(96,552) thousand in the prior-year nine months. Changes in deferred revenue contributed $66,062 thousand in operating cash flow, and research fees and grants receivable contributed $21,063 thousand, both as printed in the cash flow statement.
- Cash, cash equivalents and restricted cash at end of nine months: $190,761 thousand; total cash, cash equivalents and restricted cash on the balance sheet: $188,800 thousand.
- The press release text states over $790 million in total cash balances and marketable securities and over $890 million in total available liquidity. That includes over $100 million in available non-dilutive government funding, which the filing does not itemize in the statements. The balance sheet total is $764,424 thousand.
Analysis
AbCellera reported third-quarter 2026 total revenue of $10,639 thousand, up from $8,955 thousand, with research fees of $10,549 thousand and licensing and royalty revenue of $90 thousand. The company did not print a percentage change for revenue. On a nine-month basis, total revenue was $23,001 thousand versus $30,275 thousand, and the decline reflects licensing and royalty revenue of $431 thousand against $10,751 thousand in the prior-year period, while research fees rose to $22,570 thousand from $19,524 thousand. The filing does not explain the licensing decline beyond the figures themselves.
Cost reduction is the clearest change in the quarter. R&D expenses were $43,535 thousand against $55,028 thousand, and SG&A expenses were $13,613 thousand against $24,958 thousand. Depreciation and amortization moved the other way, to $6,806 thousand from $5,247 thousand. Total operating expenses were $63,954 thousand versus $85,233 thousand, and the loss from operations narrowed to $(53,315) thousand from $(76,278) thousand. Other income is presented as a negative figure in the statements: total other income was $(10,503) thousand against $(7,510) thousand, with interest and other at $(6,867) thousand and grants and incentives at $(3,636) thousand. The income tax recovery was $(2,054) thousand against $(11,649) thousand. Net loss came to $(40,758) thousand, or $(0.13) per share basic and diluted, compared with $(57,119) thousand, or $(0.19).
The balance sheet and cash flow changed more than the income statement. Total cash, cash equivalents and marketable securities rose to $764,424 thousand from $533,826 thousand at December 31, 2025, after the company issued common shares and pre-funded warrants for net proceeds of $188,824 thousand in the nine months. Operating cash flow was $19,313 thousand for the nine months against $(96,552) thousand a year earlier, with deferred revenue contributing $66,062 thousand. Deferred revenue on the balance sheet increased to $35,038 thousand current and $48,050 thousand long-term. The company states total cash and marketable securities of over $790 million and total available liquidity of over $890 million, including over $100 million of non-dilutive government funding. Those narrative figures differ from the $764,424 thousand balance sheet total, and the filing does not reconcile them.
Pipeline news dominated the release. The company reported positive Phase 2 top-line results for ABCL635 in vasomotor symptoms, plans late-stage menopausal VMS development in 2027, and expects to start trials in VMS associated with hormone-suppression therapy for breast and prostate cancer in 2027. Three programs entered IND-enabling work (ABCL992, ABCL385, ABCL646), and ABCL575 completed Phase 1 with the company stating it does not plan to develop it further beyond Phase 1. The number of partner-led programs with a downstream stake fell to 34 from 44 at December 31, 2025, and 12 molecules in the clinic were reported as progressing at September 30, 2026. The filing contains no guidance, so no forward figures are compared with actuals.
Overall, the quarter shows lower reported operating costs, a narrower net loss and a larger cash position following the equity raise. Revenue was higher in the quarter but lower over nine months, and the partner-program count declined. Readers should weigh the reduced expense base and the cash position against the shortfall in year-to-date licensing revenue and the absence of any guidance.
Management, verbatim
This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion.
Carl Hansen, Ph.D., Founder and CEO, AbCellera
Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes.
Carl Hansen, Ph.D., Founder and CEO, AbCellera
Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.
Carl Hansen, Ph.D., Founder and CEO, AbCellera
Not in the filing
stated, not guessed- No financial guidance for revenue, gross margin, operating expenses or tax rate is provided in the filing.
- No prior-period outlook was supplied, so no guidance comparison is possible.
- Percentage change for total revenue, operating expenses and net loss is not printed.
- Prior-quarter (Q2 2026) comparatives are not printed in the filing.
- No non-GAAP measures or reconciliations are presented.
- No segment reporting is presented beyond the revenue sub-lines.
- Free cash flow is not reported and was not computed.
- Reconciliation of the $790 million and $890 million liquidity figures in the press release to the $764,424 thousand balance sheet total is not provided.
- Composition of the over $100 million of non-dilutive government funding is not itemized.
- Nine-month prior-year and current-year figures for each cash flow line are printed, but no nine-month percentage changes are printed.
- Share price reaction and analyst consensus are not contained in the filing and were not used.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
AbCellera Biologics Inc. filed an 8‑K reporting its Q3 2026 financials and clinical updates.
Ticker impact
Q3 2026 earnings disclosed net loss of $40.8M, $200M capital raise and positive Phase 2 data for ABCL635.
likely upward pressure as market prices in the $200M liquidity boost and Phase 2 success.
First‑report earnings with sizable cash infusion and clinical data are fresh catalysts that can move price today.
Market effects
Biotech sector may see renewed interest in antibody platforms after ABCL's Phase 2 readout.
North American biotech indices could receive a modest boost.
Limited to investors focused on US‑listed biotech stocks.
Counterpoint
The net loss and high R&D spend could outweigh the cash raise, prompting a short‑term pullback.
Key entities
- companyAbCellera Biologics Inc.
Clinical‑stage biotech focused on antibody therapeutics.
